Deciphera Pharmaceuticals Management

Management criteria checks 2/4

Deciphera Pharmaceuticals' CEO is Steve Hoerter, appointed in Mar 2019, has a tenure of 5.08 years. total yearly compensation is $6.01M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth €997.25K. The average tenure of the management team and the board of directors is 4.2 years and 8.8 years respectively.

Key information

Steve Hoerter

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage	12.3%
CEO tenure	5.1yrs
CEO ownership	0.09%
Management average tenure	4.2yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Hoerter's remuneration changed compared to Deciphera Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$6m	US$738k	-US$195m
Sep 30 2023	n/a	n/a	-US$194m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$703k	-US$179m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$9m	US$676k	-US$300m
Sep 30 2021	n/a	n/a	-US$274m
Jun 30 2021	n/a	n/a	-US$258m
Mar 31 2021	n/a	n/a	-US$255m
Dec 31 2020	US$8m	US$650k	-US$266m
Sep 30 2020	n/a	n/a	-US$271m
Jun 30 2020	n/a	n/a	-US$263m
Mar 31 2020	n/a	n/a	-US$218m
Dec 31 2019	US$9m	US$435k	-US$192m
Sep 30 2019	n/a	n/a	-US$157m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$126m
Dec 31 2018	US$447k	n/a	-US$100m

Compensation vs Market: Steve's total compensation ($USD6.01M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Hoerter (52 yo)

5.1yrs

Tenure

US$6,010,712

Compensation

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Hoerter	President	5.1yrs	US$6.01m	0.089% $ 997.2k
Thomas Kelly	Executive VP	9.2yrs	US$2.03m	0.052% $ 582.2k
Dashyant Dhanak	Executive VP & Chief Scientific Officer	less than a year	US$3.06m	0% $ 0
Daniel Martin	Senior VP & Chief Commercial Officer	5.6yrs	US$1.58m	0.038% $ 429.4k
Matthew Sherman	Executive VP & Chief Medical Officer	4.5yrs	US$2.13m	0.088% $ 990.0k
Kevin Brodbeck	Senior VP & Chief Technical Officer	less than a year	no data	no data
Jennifer Larson	Senior Vice President of Finance & Investor Relations	no data	no data	no data
Jeffrey Held	Senior VP & General Counsel	5.1yrs	no data	no data
Lisa Price	Senior VP & Chief Human Resources Officer	2.3yrs	no data	no data
Jama Pitman	Senior VP & Chief Development Officer	4.2yrs	no data	0.042% $ 469.3k
Margarida Duarte	Senior VP & Head of International	3.2yrs	no data	no data
Rodrigo Soto	Senior Vice President of Clinical Development	3.3yrs	no data	no data

4.2yrs

Average Tenure

52yo

Average Age

Experienced Management: D05's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Hoerter	President	5.9yrs	US$6.01m	0.089% $ 997.2k
John Martin	Independent Director	9.2yrs	US$388.59k	0% $ 0
Edward Benz	Independent Director	7.5yrs	US$396.09k	0% $ 0
Patricia L. Allen	Independent Director	7.6yrs	US$398.55k	0% $ 0
Ron Squarer	Independent Chairman	4.3yrs	US$403.30k	0% $ 0
Jean-Yves Blay	Member of Scientific Advisory Board	8.8yrs	no data	no data
James Bristol	Independent Director	16.7yrs	US$414.77k	0% $ 0
John Condeelis	Member of Scientific Advisory Board	no data	no data	no data
Filip Janku	Member of Scientific Advisory Board	8.8yrs	no data	no data
F. Hodi	Member of Scientific Advisory Board	8.8yrs	no data	no data
Dennis Walsh	Independent Director	9.2yrs	US$386.05k	0.013% $ 150.8k
John de Groot	Member of Scientific Advisory Board	no data	no data	no data

8.8yrs

Average Tenure

61yo

Average Age

Experienced Board: D05's board of directors are considered experienced (8.8 years average tenure).

Deciphera Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

President recently sold €437k worth of stock

Senior VP & Chief Commercial Officer recently sold €205k worth of stock

President recently sold €244k worth of stock

President recently sold €244k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Recent updates

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Full year 2023 earnings released: US$2.29 loss per share (vs US$2.37 loss in FY 2022)

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold €437k worth of stock

Senior VP & Chief Commercial Officer recently sold €205k worth of stock

President recently sold €244k worth of stock

President recently sold €244k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings released: US$0.58 loss per share (vs US$0.55 loss in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.57 loss per share (vs US$0.60 loss in 2Q 2022)

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Now 22% undervalued after recent price drop

Independent Director recently bought €139k worth of stock

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.37 loss per share (vs US$5.16 loss in FY 2021)

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Now 21% undervalued

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

Insufficient new directors

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.37 loss in 3Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$1.22 loss in 2Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings released: US$0.80 loss per share (vs US$1.06 loss in 1Q 2021)

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020)

Executive VP & Chief Medical Officer recently sold €76k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Second quarter 2021 earnings released: US$1.22 loss per share (vs US$1.20 loss in 2Q 2020)

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

First quarter 2021 earnings released: US$1.06 loss per share (vs US$1.36 loss in 1Q 2020)

New 90-day low: €34.40

Full year 2020 earnings released: US$4.78 loss per share (vs US$4.49 loss in FY 2019)

Revenue beats expectations

Deciphera Pharmaceuticals, Inc. Announces Appointment of Margarida Duarte as Senior Vice President, Head of International

Deciphera Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 09, 2021

New 90-day low: €38.20

New 90-day low: €43.00

Deciphera Pharmaceuticals, Inc. Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

New 90-day high: €54.50

Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

Revenue beats expectations

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize Qinlock (Ripretinib)

Specialised Therapeutics Asia Signs an Agreement with Deciphera Pharmaceuticals, Inc. to Commercialise the Switch-Control Tyrosine Kinase Inhibitor QINLOCK (ripretinib)

Deciphera Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €52.50

New 90-day high: €48.20

Deciphera Pharmaceuticals, Inc. Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology Virtual Congress 2020

Deciphera Pharmaceuticals, Inc. Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020